Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Mallinckrodt (MNK) Announces H.P. Acthar Gel Pilot Study Missed Primary Endpoint in SLE

November 9, 2015 6:33 AM EST

Data presented yesterday by researchers for Mallinckrodt plc (NYSE: MNK) suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy. The pilot study data were presented at a poster session during the 2015 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Francisco being held Nov. 7-11, 2015.

"Acthar demonstrated clinically relevant improvement in signs and symptoms of lupus in patients who need an alternative therapy for persistent symptoms,"... More